KCNQ3 Protein is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
Structure
...
KCNQ3 Protein
Potassium Voltage-Gated Channel Subfamily Q Member 3
KCNQ3 Protein is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
Structure
The KCNQ3 protein is a voltage-gated potassium channel subunit consisting of six transmembrane segments (S1-S6), with the S4 segment serving as the voltage sensor. The channel assembles as a tetramer, typically forming heteromultimeric channels with KCNQ2 subunits[@maleticsavatic2019]. The pore region is located between S5 and S6 transmembrane helices. The N-terminus contains sites for regulatory protein interactions, while the C-terminus harbors the assembly domain and binding sites for phosphatidylinositol 4,5-bisphosphate (PIP₂), which is essential for channel activation.
Normal Function in the Nervous System
KCNQ3 (Kv7.3) is a key subunit of the M-channel, a voltage-gated potassium channel that regulates neuronal excitability in the central and peripheral nervous systems. The M-channel mediates the M-current, a slow, non-inactivating potassium current that controls neuronal firing frequency and spike timing adaptation[@maleticsavatic2019].
M-channel dysfunction contributes to neuronal hyperexcitability in AD. [Aβ](/proteins/amyloid-beta) oligomers impair KCNQ2/3 channel function, leading to increased excitotoxicity[@plant2020]. Loss of M-current may exacerbate calcium dysregulation and [tau](/proteins/tau) pathology. Therapeutic potential: KCNQ activators (retigabine) show promise in AD models.
Parkinson's Disease (PD)
Basal ganglia neuronal firing patterns are affected by M-channel alterations. KCNQ3 dysfunction may contribute to dopaminergic neuron vulnerability. Channel activators may provide neuroprotection against excitotoxicity.
Epilepsy and BFNS
KCNQ3 mutations cause Benign Familial Neonatal Seizures (BFNS)[@singh2012]. Heterozygous mutations lead to neonatal seizures that typically resolve. Some mutations cause ongoing epilepsy with neurodevelopmental delay.
Amyotrophic Lateral Sclerosis (ALS)
Motor neuron hyperexcitability involves M-channel dysfunction[@wainger2021]. KCNQ2/3 channel activators may reduce motor neuron excitotoxicity. Emerging therapeutic target for ALS.
[Maletic-Savatic M, et al, Molecular basis for KCNQ2/3 channel assembly (2019)](https://pubmed.ncbi.nlm.nih.gov/30692276/)
[Singh NA, et al, KCNQ3 mutations cause benign familial neonatal seizures (2012)](https://pubmed.ncbi.nlm.nih.gov/22544363/)
[Plant LD, et al, Amyloid-beta impairs KCNQ2/3 M-cannels and contributes to neuronal hyperexcitability in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32847941/)
[Wainger BJ, et al, M-channel dysfunction contributes to motor neuron hyperexcitability in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33970207/)